American children under the age of five may not be vaccinated until mid-2022, as Pfizer said Friday that it’s going to now test a third dose of its Covid-19 vaccine in the trial. The decision comes as…
Amid a very difficult back half of the year for biotech investing, some bullish investors are making the case for a major rally in the coming year as pharma looks to utilize its growing mountain of…
Jamil Rivers went from metastatic breast cancer patient to advocate to non-profit founder – all in her pursuit of breast cancer healthcare equity for Black women. Her mission began a few years ago…
The European Medicines Agency announced Friday it recommended the European Commission reject Aduhelm, dealing a new — albeit expected — blow to Biogen’s hopes of finding a widespread market for its…
Stigma around lung cancer likely isn’t going away — the ‘you did it to yourself’ critics continue no matter the statistics or circumstances presented. So instead Novartis is encouraging people with…
Well, Purdue Pharma’s multi-billion dollar opioid settlement is now in jeopardy — a federal judge just said no. Colleen McMahon, a judge on the US District Court for the Southern District of New York,…
The deal folds Soliton’s flagship Resonic tattoo- and cellulite-removal device into the portfolio of AbbVie’s medical aesthetics subsidiary.
With 150 biotechs to its name, Omega Funds closed its seventh and largest fund with $650 million to incubate drug developers, lead early financing rounds and back older startups on the brink of…
Just like its approval request for a phase 2 ALS drug, Amylyx Pharmaceuticals is once again skirting convention and going forward with an initial public offering when the biotech market appears to be…
Using information collected from more than 13,700 participants in an Amgen clinical trial, Owkin’s AI spotted which people had the highest risks of heart attacks or stroke.
